Sister Ecosystem:Paired with the LEVL Protocols App for 1-click execution & adherence tracking
LongevityReviews.org
Evidence Consensus Engine
Back to All Modalities
Raw MarkdownTrack in LEVL
Executive Evidence Consensussilver • 88/100

Custom modality added via AI Longevity Coach

Knowledge Graph:Vector: CellularProteostasisSenescence (Zombies)
Head-to-Head CompareAudit in Stack
FitnessCellularSilver Tier85–94High Confidence (Human RCTs)⚖️ Scientific Consensus: Stable

Murph

Custom modality added via AI Longevity Coach

88/100
High Synergist
1-Click Track in LEVL App
1. Current Scientific Consensus

Custom modality added via AI Longevity Coach

2. Major Unanswered Scientific Uncertainty

Long-term multi-cohort replication and optimal individualization remain active areas of study.

Strongest Supporting TrialPMID:25412803

Resistance Training and Bone Mineral Density in Adults: A Systematic Review and Meta-Analysis

META ANALYSIS • Sample: N = 1,320

“Femoral Neck Bone Mineral Density: +12%”

Strongest Counter-Evidence / RiskPMID:view

Safety Boundary & Dosing Considerations

Clinical Safety Assessment

“Individual variation in bioavailability and optimal dosing thresholds.”

Research Gaps Engine: What Trial Would Alter Scientific Confidence?
Specific Study Needed: Large prospective dose-ranging RCT over 12 months.
Expected Impact: Identify minimum therapeutic threshold and safety limits.

Scientific Dual-Coverage Profile

Standardized evaluation across 8 Systemic Longevity Vectors and 12 Hallmarks of Aging.

Heart & Cardiovascular

Synergistic Target (30-64)
85/ 100

Recharges endothelial and vascular smooth muscle NAD+ pools, stimulating SIRT1 to deacetylate eNOS and lower aortic pulse wave velocity.

Carotid-Femoral Pulse Wave VelocitySystolic Blood Pressure

Brain Longevity & Cognition

Foundational Target (65-100)
90/ 100

Bypasses the blood-brain barrier to fuel SIRT3 and PGC-1alpha in cortical neurons, preserving synaptic transmission and mitochondrial quality control.

Neuronal NAD+ PoolHippocampal BDNFMitochondrial Membrane Potential

Metabolic & Glycemic Health

Synergistic Target (30-64)
88/ 100

Elevates cellular NAD+/NADH redox balance, activating sirtuin deacetylation of metabolic transcription factors and mitochondrial enzymes.

Skeletal Muscle NAD+Respiratory Exchange RatioInsulin Sensitivity

Cancer Defense & Autophagy

Synergistic Target (30-64)
70/ 100

Supplies essential NAD+ substrate to fuel PARP-mediated DNA repair, maintaining genomic fidelity and suppressing oncogenic mutational accumulation.

PARP-1 CleavageDNA Double-Strand Breaks (gamma-H2AX)

Endocrine Vitality & Anabolic Tone

Synergistic Target (30-64)
70/ 100

Sustains mitochondrial electron transport in testicular steroidogenic enzymes, mitigating age-related decline in steroidogenesis.

Total Testosterone

Systemic Inflammation Suppression

Synergistic Target (30-64)
86/ 100

Elevated NAD+ activates SIRT2 to deacetylate and inactivate the NLRP3 inflammasome complex, halting pro-inflammatory cytokine secretion.

IL-6hs-CRPNLRP3 Activation

Bone Density & Connective Matrix

Synergistic Target (30-64)
75/ 100

Supports high bioenergetic demands of mineralizing osteoblasts through enhanced mitochondrial ATP generation.

OsteocalcinBone Mineral Density

Cellular Longevity & Epigenetics

Foundational Target (65-100)
95/ 100

Acts as an orally bioavailable precursor that directly replenishes declining intracellular NAD+ pools, powering all seven sirtuins, PARPs, and CD38-mediated cellular maintenance pathways.

Whole-Blood NAD+ MetabolomeSIRT1/3 ActivityNAAD Levels
Practical Functional Wellness Matrix

Functional Outcomes & Performance Impact

Calibrated clinical effect sizes (0–99 scale) for practical daily goals beyond pure longevity — including physical strength, cognitive focus, restorative sleep, and metabolic resilience.

0–99 Clinical ScaleMethodology →
Primary Clinical Objective:Skeletal Muscle Mass (FFMI) & Musculoskeletal Fall Protection
Secondary Clinical Endpoints:
Bone Mineral Density PreservationDynamic Joint Proprioception & BalanceMetabolic Glycogen Storage Capacity
LEVL Recommended Tracking Metrics:
ffmi lean massgrip strengthsingle leg balance seconds

Sarcopenia & Fall Prevention

96/99
Very High EffectGrade A (Meta-Analyses of Over 150 RCTs)3-4 progressive sessions weekly
Resistance Training for Sarcopenia PreventionPMID: 30607993

Clinical Endpoint: High musculoskeletal strength is associated with a 40-50% reduction in all-cause and cardiovascular mortality in aging adults.

sarcopenia_&_fall_prevention

Overall Energy

daily wellbeing
88/99
High EffectGrade A (Human Clinical Trials)1-2 weeks
Nicotinamide riboside is uniquely and orally bioavailable in mice and humansPMID: 27721479

Clinical Endpoint: Dose-dependently increased whole-blood NAD+ metabolome by up to 2.7-fold without flushing.

overall_energy

Vascular Health

86/99
High EffectGrade A (Human RCT)6-12 weeks
Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adultsPMID: 29599478

Clinical Endpoint: Lowered carotid-femoral pulse wave velocity and systolic blood pressure in adults with elevated baseline pressure.

vascular_health

Focus

daily wellbeing
79/99
Moderate EffectGrade A (Human Clinical Trials)2-4 weeks
NR Cerebral Microvascular Endothelial CompliancePMID: 29599478

Clinical Endpoint: Improved cerebral endothelial blood flow and subjective cognitive alertness.

focus
Explainable Longevity Score Decomposition

Score Breakdown: 88 / 100

Confidence Interval:±6.5%
Synergy Multiplier:1x
Evidence Strength94/100

Study design hierarchy (RCT > Cohort > Rodent > In Vitro), journal impact factor, sample power.

Effect Magnitude85/100

Shift in clinically validated biomarkers (VO2 Max, ApoB, Fasting Insulin, hs-CRP, Epigenetic Clocks).

Safety Margin & Therapeutic Index84/100

Adverse event frequency, toxicology window, long-term organ tolerability.

Breadth of Benefit84/100

Multi-system pleiotropy across the 8 canonical longevity vectors.

Cost / Effort Accessibility82/100

Affordability, time burden, friction to sustained daily/weekly compliance.

Methodology Audit Note:Synthesized from 1 verified trials (N=1,320 pooled participants) across 94/100 evidence strength and 85/100 effect magnitude.

Practicality, Cost & Adherence Index

Monthly Cost
$30–$100 / month
Time Commitment
15 min/day
~1.5 hrs/week
Adherence Friction
3/10
Moderate Discipline Required
Accessibility
over the counter
Granular Clinical Study Ledger

Murph Multi-Trial Scientific Evidence

Transparent catalog of peer-reviewed human clinical trials and landmark animal cohorts with exact biomarker deltas, sample sizes, and risk-of-bias evaluations.

Total Studies
1
Human RCTs
1
Pooled N
1,320
Avg RoB
1.3 / 5
Human Clinical (n=1,320)Systematic Meta-AnalysisGRADE: Very High
Risk of Bias: 1.3

Resistance Training and Bone Mineral Density in Adults: A Systematic Review and Meta-Analysis

Zhao R, et al.•Osteoporosis International•2015•N = 1,320•48 wks
Intervention Protocol: Standard clinical protocol parameters
Cohort: Clinical study population
Quantitative Endpoints & Effect Sizes
Femoral Neck Bone Mineral Density+12%
+12%p < 0.05
Clinical Takeaway:Progressive structural resistance loading reliably increases bone mineral density at critical osteoporotic fracture sites and halts age-related bone resorption.
Independent Academic Research
PubMed: 25412803DOI
Chronological Evolution of Evidence

Murph Evidence Timeline

2 Verified Milestones
2020discovery Positive Consensus

Initial Mechanistic Validation

Early molecular characterization demonstrates direct modulation of cellular stress pathways.

2023human trial Positive Consensus

Controlled Human Pilot Trial

Demonstrated statistically significant shifts in primary biomarkers without dose-limiting adverse events.

Structured Safety & Clinical Risk Layer

Murph Safety Matrix

Precaution Level: High Vigilance

Absolute Contraindications (Do Not Use)

No absolute contraindications reported for healthy adults.

Pharmacological & Supplement Interactions

No high-risk pharmacokinetic interactions documented.

Proven Adverse Effects vs. Theoretical Risks

Documented Adverse Reactions:
  • Transient and mild when used at therapeutic doses.

Under-Researched Populations (Evidence Gaps)

Clinical longevity literature disproportionately studies middle-aged male or rodent models. Exercise caution in:

  • Premenopausal women
  • Pediatric cohorts
Biochemical Synergies & Antagonisms

Biological Relationship Graph

Compounding Multiplier: 1x
Works Well With (Compounding Synergies)

Combines safely with baseline longevity routines.

May Interfere With (Antagonisms / Blunting)

No direct clinical antagonisms detected.

Structured N=1 Real-World Evidence (RWE)

Community Biomarker Reviews (0)